Form 4: Nuvectis Pharma Executive Shay Shemesh Reports Acquisition of 150,000 Shares of Restricted Common Stock

Shay Shemesh, Chief Development & Operations Officer of Nuvectis Pharma, reports acquiring 150,000 shares of restricted common stock on January 2, 2025.

Summary

• On January 2, 2025, Shay Shemesh, the Chief Development & Operations Officer of Nuvectis Pharma, acquired 150,000 shares of restricted common stock.
• These shares were acquired at a price of $0.
• The shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, contingent upon Mr. Shemesh's continued service.
• Following this transaction, Mr. Shemesh beneficially owns 1,643,068 shares of common stock, which includes 503,399 shares of restricted stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock acquisition by an executive, which can be seen as a positive sign of confidence, but it doesn't inherently indicate significant positive or negative news.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock is contingent upon Mr. Shemesh's continued service with the company over the next three years.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company executives.

Stakeholder Impact

• The acquisition of shares by a key executive could positively influence shareholder sentiment.

Key Dates